Uniplan Investment Counsel’s Royalty Pharma RPRX Stock Holding History

Uniplan Investment Counsel’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.89M	Sell	87,198 -1,540	-2%	-$80.2K	0.46%	64
2026 Q1	$4.26M	Sell	88,738 -3,008	-3%	-$132K	0.44%	64
2025 Q4	$3.55M	Buy	91,746 +19,930	+28%	+$760K	0.36%	78
2025 Q3	$2.53M	Buy	71,816 +11,749	+20%	+$425K	0.25%	97
2025 Q2	$2.16M	Buy	60,067 +8,229	+16%	+$273K	0.22%	103
2025 Q1	$1.61M	Buy	51,838 +11,904	+30%	+$377K	0.16%	113
2024 Q4	$1.02M	Buy	+39,934	New	+$1.06M	0.09%	127

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Uniplan Investment Counsel's RPRX Position: Q2 2026 in Review

Uniplan Investment Counsel reduced its Royalty Pharma (RPRX) stake by 1.7% in Q2 2026, selling an estimated $80.2K and leaving 87,198 shares worth $4.89M. The position accounts for 0.46% of the portfolio, ranked #64.

Uniplan Investment Counsel first reported a position in RPRX in Q4 2024 and has held it in 7 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Uniplan Investment Counsel held 87,198 shares of Royalty Pharma worth $4.89M as of Q2 2026.
Uniplan Investment Counsel sold 1,540 Royalty Pharma shares in Q2 2026, an estimated $80.2K.
Royalty Pharma made up 0.46% of Uniplan Investment Counsel's portfolio in Q2 2026, its #64 holding.
Uniplan Investment Counsel first reported a position in Royalty Pharma in Q4 2024 and has held it in 7 quarters since.
645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Uniplan Investment Counsel's 13F filing for Q2 2026, filed 13 Aug 2026.